Table 2 Effect of intensive education on the stroke management ability of community doctors

Knowledge of relevant guidelines

140 (37.8)

265 (68.1)

< 0.001

Classification of stroke

301 (81.4)

351 (90.2)

< 0.001

Knowledge of stroke warning signs

< 0.001

 0

129 (34.9)

79 (20.3)

 1

62 (16.8)

91 (23.4)

 2

49 (13.2)

42 (10.8)

 3

63 (17.0)

51 (13.1)

 4

41 (11.1)

75 (19.3)

0.918

 5

26 (7.0)

51 (13.1)

Pre-hospital stroke assessment methods

9 (2.4)

109 (28.0)

Management of acute ischemic stroke in community health centers (stations)

< 0.001

 0 score

289 (78.1)

201 (51.7)

< 0.001

 1 score

26 (7.0)

50 (12.9)

 2 score

21 (5.7)

41 (10.5)

 3 score

13 (3.5)

37 (9.5)

 4 score

10 (2.7)

28 (7.2)

Score ≥ 5

11 (3.0)

32 (8.2)

Thrombolytic therapy for acute ischemic stroke

329 (88.9)

351 (90.2)

0.554

Time window for thrombolytic therapy

149 (45.3)

214 (61.0)

< 0.001

Risk factors for stroke

< 0.001

 0

108 (29.2)

54 (13.9)

 1

30 (8.1)

25 (6.4)

 2

44 (11.9)

28 (7.2)

 3

72 (19.5)

97 (24.9)

 4

77 (20.8)

87 (22.4)

Score ≥ 5

39 (10.5)

98 (25.2)

Definition of TIA

159 (43.0)

202 (51.9)

0.014

TIA management in community health centers

51 (13.8)

105 (27.0)

< 0.001

General goal for target BP level for the prevention of recurrent stroke

247 (66.8)

289 (74.3)

0.023

Ideal goal for target BP level for the prevention of recurrent stroke

170 (45.9)

215 (55.3)

0.010

Goal for target HbA1c level for the prevention of recurrent stroke

152 (41.1)

239 (61.4)

< 0.001

Goal for BP for the prevention of recurrent stroke in hypertensive patients with diabetes

152 (41.1)

239 (61.4)

< 0.001

Awareness of statins therapy for the prevention of recurrent stroke

199 (53.8)

301 (77.4)

< 0.001

General goals for LDL-c level for the prevention of recurrent stroke

28 (7.6)

107 (27.5)

< 0.001

Side effects of statins

0.296

abnormal liver function

45 (12.2)

103 (26.5)

muscle damage

30 (8.10

89 (22.9)

knowing both side effects

41 (11.1)

78 (20.1)

Goals for LDL-c level for the prevention of recurrent stroke in patients associated with multiple risk factors or evidence for atherosclerotic vulnerable plaque or arterial embolism

31 (8.4)

95 (24.2)

< 0.001

Awareness of warfarin therapy for the prevention of recurrent stroke in patients with atrial fibrillation

165 (44.6)

278 (71.5)

< 0.001

Goal for INR level in patients who receive warfarin therapy

108 (65.5)

217 (78.1)

0.004

Awareness of antiplatelet therapy for the prevention of recurrent stroke

88 (23.8)

189 (48.6)

< 0.001